Biological
CART-19 cells
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(17%)
Phase Distribution
Ph phase_1
3
50%
Ph phase_2
3
50%
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Terminated(1)
Other(5)
Detailed Status
unknown5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (50.0%)
Phase 23 (50.0%)
Trials by Status
unknown583%
terminated117%
Recent Activity
0 active trials
Showing 5 of 6
terminatedphase_2
CART-19 Post-ASCT for Multiple Myeloma
NCT02794246
unknownphase_1
CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL
NCT05270772
unknownphase_1
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
NCT03544021
unknownphase_2
CART-19 Cells For R/R B-ALL
NCT03391739
unknownphase_2
CART-19 Cells for R/R B-cell Lymphoma
NCT03391726
Clinical Trials (6)
Showing 6 of 6 trials
NCT02794246Phase 2
CART-19 Post-ASCT for Multiple Myeloma
NCT05270772Phase 1
CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL
NCT03544021Phase 1
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
NCT03391739Phase 2
CART-19 Cells For R/R B-ALL
NCT03391726Phase 2
CART-19 Cells for R/R B-cell Lymphoma
NCT02924753Phase 1
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6